Susanna Gatti High - 21 Jun 2024 Form 4/A Insider Report for Dyne Therapeutics, Inc. (DYN)

Role
Chief Operating Officer
Signature
/s/ Richard Scalzo, Attorney-in-Fact
Issuer symbol
DYN
Transactions as of
21 Jun 2024
Net transactions value
-$1,182,068
Form type
4/A
Filing time
03 Jul 2024, 21:00:02 UTC
Date Of Original Report
24 Jun 2024
Previous filing
13 Jun 2024
Next filing
20 Aug 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction DYN Common Stock Options Exercise $165,020 +29,787 +20% $5.54 178,579 21 Jun 2024 Direct
transaction DYN Common Stock Sale $1,042,843 -29,787 -17% $35.01 148,792 21 Jun 2024 Direct F1, F2
transaction DYN Common Stock Options Exercise $56,580 +10,213 +6.9% $5.54 159,005 24 Jun 2024 Direct F3
transaction DYN Common Stock Sale $360,825 -10,213 -6.4% $35.33 148,792 24 Jun 2024 Direct F1, F3, F4, F5

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction DYN Stock option (right to buy) Options Exercise $0 -29,787 -30% $0.000000 70,699 21 Jun 2024 Common Stock 29,787 $5.54 Direct F6
transaction DYN Stock option (right to buy) Options Exercise $0 -10,213 -14% $0.000000 60,486 24 Jun 2024 Common Stock 10,213 $5.54 Direct F3, F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 11, 2024.
F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $35.00 to $35.11, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range(s) set forth in the footnotes of this Form 4.
F3 This Form 4/A is being filed to correct the number of stock options exercised and subsequent shares of common stock sold as reported in Tables I and II of the original Form 4 filed on June 24, 2024, which inadvertently reported 10,163 stock options exercised and subsequent shares of common stock sold instead of the 10,213 shares reported herein.
F4 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $35.00 to $35.63, inclusive.
F5 Includes 134,629 unvested RSUs.
F6 The option was granted on July 31, 2020. The shares underlying the option vest over four years, with 25% of the shares vesting on July 31, 2021 and the remaining shares vesting in equal quarterly installments thereafter.